SCHEMBL7816152

SCHEMBL7816152

CC(=O)CC(=O)C(F)(F)C(F)(F)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.36
MGAM O43451 1/20 0.33
GAA P10253 1/20 0.33
SI P14410 1/20 0.33
MGAM2 Q2M2H8 1/20 0.33
HTT P42858 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
MMP1 P03956 1/20 0.31
MMP2 P08253 1/20 0.31
MMP9 P14780 1/20 0.31
MMP8 P22894 1/20 0.31
MMP13 P45452 1/20 0.31
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
KDM4E B2RXH2 1/20 0.30
KDM6B O15054 1/20 0.30
KDM5C P41229 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20690112 0.93 THRB (0.44) THRBMGAMGAASIMGAM2
SCHEMBL9336454 0.91 THRB (0.48) THRBMGAMGAASIMGAM2
SCHEMBL22246156 0.91 THRB (0.48) THRBMGAMGAASIMGAM2
Silver SCHEMBL30466752 0.91 THRB (0.43) THRBMGAMGAASIMGAM2
SCHEMBL5467545 0.85 LIPA (0.38) MGAMGAASIMGAM2HTT
SCHEMBL2221105 0.85 THRB (0.42) THRBCA1CA2MMP1MMP2
SCHEMBL20453952 0.79 THRB (0.34) THRBCA1CA2MMP1MMP2
SCHEMBL26493732 0.79 THRB (0.34) THRBCA1CA2MMP1MMP2
SCHEMBL196683 0.79 THRB (0.34) THRBCA1CA2MMP1MMP2
SCHEMBL939341 0.78 THRB (0.37) THRBCA2ALDH1A1POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643561-B2 Process for the preparation of metallic nano-particle layers and their use for decorative or security elements BASF SE 2023-05-09 US disclosed
US-11643561-B2 Process for the preparation of metallic nano-particle layers and their use for decorative or security elements BASF SE 2023-05-09 US disclosed
US-20200230646-A1 PROCESS FOR THE PREPARATION OF METALLIC NANO-PARTICLE LAYERS AND THEIR USE FOR DECORATIVE OR SECURITY ELEMENTS BASF SE (DE) 2020-07-23 US disclosed
US-20170253623-A1 IRIDIUM COMPLEX PRODUCTION METHOD TANAKA KIKINZOKU KOGYO K.K. (JP) 2017-09-07 US disclosed
EP-1117650-A2 USE OF SUBSTITUTED 5-HYDROXYPYRAZOLES, NOVEL 5-HYDROXYPYRAZOLES, METHODS FOR THE PRODUCTION THEREOF AND AGENTS CONTAINING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2001-07-25 EP disclosed
WO-2000020399-A2 USE OF SUBSTITUTED 5-HYDROXYPYRAZOLES, NOVEL 5-HYDROXYPYRAZOLES, METHODS FOR THE PRODUCTION THEREOF AND AGENTS CONTAINING THE SAME BASF AKTIENGESELLSCHAFT (DE) 2000-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253623-A1 IRIDIUM COMPLEX PRODUCTION METHOD IPMK, TALDO1, BCKDK THRB 1343/4885MGAM 566/4885GAA 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.